<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02213003</url>
  </required_header>
  <id_info>
    <org_study_id>20140144</org_study_id>
    <nct_id>NCT02213003</nct_id>
  </id_info>
  <brief_title>Allogeneic Islet Cells Transplanted Onto the Omentum</brief_title>
  <official_title>Allogeneic Islet Cells Transplanted Onto the Omentum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rodolfo Alejandro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diabetes Research Institute Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current islet transplantation into the portal vein of the liver has shown the unique ability&#xD;
      of islets to stabilize blood glucose levels and prevent severe hypoglycemia in a selected&#xD;
      group of subjects with Type 1 diabetes. The main limitations of islet transplantation are the&#xD;
      need for systemic immunosuppression to maintain function and the loss of islet function over&#xD;
      time. Additionally, many studies have demonstrated that the current site of transplantation&#xD;
      in the liver is not an ideal site due to several factors. These factors include (1)&#xD;
      significant liver inflammation following islet infusion; (2) potential for life-threatening&#xD;
      procedure-related complications such as bleeding and thrombosis; (3) high levels of&#xD;
      immunosuppressive drugs and GI toxins in the liver contributing to islet toxicity; (4) the&#xD;
      inability to retrieve islets after infusion; and (5) development of graft dysfunction in a&#xD;
      number of recipients of intrahepatic allogeneic and autologous islets. The implantation of&#xD;
      islets into the omentum will allow adequate engraftment of islets onto the omentum and will&#xD;
      lead to comparable or superior functional and clinical outcomes than in the traditional&#xD;
      intrahepatic site.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Islet transplantation will be performed in subjects with unstable Type 1 diabetes mellitus&#xD;
      under permanent immunosuppression. Islets are re-suspended in autologous plasma and&#xD;
      distributed on the omental surface by a minimal invasive approach. Cell adherence is achieved&#xD;
      by addition of clinical-grade recombinant human thrombin that reacts with plasma to create a&#xD;
      biocompatible, degradable gel containing the islet graft. The primary efficacy endpoint is&#xD;
      the proportion of subjects with HbA1c ≤6.5% at 1 year AND free of severe hypoglycemic events&#xD;
      from Day 28 to Day 365, inclusive, after the islet transplant. The primary safety endpoint is&#xD;
      to demonstrate patient safety throughout all stages of the trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A1c &lt;/= 6.5% and no severe hypoglycemia</measure>
    <time_frame>1 year</time_frame>
    <description>composite outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>procedural complications</measure>
    <time_frame>1 year</time_frame>
    <description>safety</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Hypoglycemia</condition>
  <condition>Hypoglycemia Unawareness</condition>
  <arm_group>
    <arm_group_label>Islet transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transplantation of at least 5000 islet equivalents/kg of body weight onto the omentum.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Islet transplantation</intervention_name>
    <description>Transplantation of at least 5000 islet equivalents/kg of body weight onto the Omentum.</description>
    <arm_group_label>Islet transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patients age 18 to 65 years of age.&#xD;
&#xD;
          2. Ability to provide written informed consent.&#xD;
&#xD;
          3. Mentally stable and able to comply with the procedures of the study protocol.&#xD;
&#xD;
          4. Type1 diabetes with onset of disease at &lt;40 years of age, insulin-dependence for &gt; 5&#xD;
             years at the time of enrollment&#xD;
&#xD;
          5. Absent stimulated c-peptide (&lt;0.3ng/mL) in response to a mixed meal tolerance test.&#xD;
&#xD;
          6. Involvement in intensive diabetes management&#xD;
&#xD;
          7. At least one episode of severe hypoglycemia in the 12 months prior to study&#xD;
             enrollment.&#xD;
&#xD;
          8. Reduced awareness of hypoglycemia as defined by a Clarke score of 4 or more OR A&#xD;
             Hypoglycemia score greater than or equal to the 90th percentile (1047) during the&#xD;
             screening period; OR Marked glycemic lability and defined by a lability index score&#xD;
             greater than or equal to the 90th percentile (433 mmol/L2/h•wk-1) during the screening&#xD;
             period; OR A composite of a Clarke score of 3 or less and a hypoglycemia score greater&#xD;
             than or equal to the 75th percentile (423) and a lability index greater than or equal&#xD;
             to the 75th percentile (329) during the screening period.&#xD;
&#xD;
          9. Subjects screening data from 20053135 protocol will be accepted for subjects eligible&#xD;
             for this study. If 20053135 visit was 12 months prior to enrollment, Visit 2&#xD;
             laboratory should be repeated.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Body Mass Index (BMI) &gt;30 kg/m2 or patient weight ≤50 kg.&#xD;
&#xD;
          2. Insulin requirement of &gt;1.0 IU/kg/day or &lt;15 U/day.&#xD;
&#xD;
          3. HbA1c &gt;10%.&#xD;
&#xD;
          4. Untreated proliferative diabetic retinopathy.&#xD;
&#xD;
          5. Blood Pressure: SBP &gt;160 mmHg or DBP &gt;100 mmHg.&#xD;
&#xD;
          6. Glomerular filtration rate &lt;80 mL/min/1.73 m2 (calculated).&#xD;
&#xD;
          7. Presence or history of macroalbuminuria (&gt;300mg/g creatinine).&#xD;
&#xD;
          8. Presence or history of panel-reactive anti-HLA antibodies.&#xD;
&#xD;
          9. For female subjects: Serum or urine Positive pregnancy test, presently breast-feeding,&#xD;
             or unwillingness to use effective contraceptive measures for the duration of the study&#xD;
             and 4 months after discontinuation. For male subjects: intent to procreate during the&#xD;
             duration of the study or within 4 months after discontinuation or unwillingness to use&#xD;
             effective measures of contraception. If sexually active, subject must use at least two&#xD;
             medically accepted methods of birth control.&#xD;
&#xD;
         10. Presence or history of active infection including hepatitis B, hepatitis C, HIV, or&#xD;
             tuberculosis (TB).&#xD;
&#xD;
         11. Negative screen for Epstein-Barr Virus (EBV) by IgG determination.&#xD;
&#xD;
         12. Invasive aspergillus, histoplasmosis, and coccidioidomycosis infection within one year&#xD;
             prior to study enrollment.&#xD;
&#xD;
         13. Any history of malignancy except for completely resected squamous or basal cell&#xD;
             carcinoma of the skin.&#xD;
&#xD;
         14. Active alcohol or substance abuse.&#xD;
&#xD;
         15. Hb below the lower limits of normal at the local laboratory; lymphopenia (&lt;1,000/µL),&#xD;
             neutropenia (&lt;1,500/µL), or thrombocytopenia (platelets &lt;100,000/µL).&#xD;
&#xD;
         16. A history of Factor V deficiency.&#xD;
&#xD;
         17. Any coagulopathy or medical condition requiring long-term anticoagulant therapy.&#xD;
&#xD;
         18. Severe co-existing cardiac disease,&#xD;
&#xD;
               1. recent myocardial infarction (within past 6 months)&#xD;
&#xD;
               2. evidence of ischemia on functional cardiac exam within the last year) left&#xD;
                  ventricular ejection fraction &lt;30%.&#xD;
&#xD;
         19. Persistent elevation of liver function tests at the time of study entry.&#xD;
&#xD;
         20. Symptomatic cholecystolithiasis.&#xD;
&#xD;
         21. Acute or chronic pancreatitis.&#xD;
&#xD;
         22. Symptomatic peptic ulcer disease.&#xD;
&#xD;
         23. Gastrointestinal disorders potentially interfering with the ability to absorb oral&#xD;
             medications.&#xD;
&#xD;
         24. Hyperlipidemia despite medical therapy (fasting LDL cholesterol &gt; 130 mg/dL, fasting&#xD;
             triglycerides &gt; 200 mg/dl).&#xD;
&#xD;
         25. Chronic use of systemic steroids, except for the use of ≤5 mg prednisone daily, or an&#xD;
             equivalent dose of hydrocortisone, for physiological replacement only.&#xD;
&#xD;
         26. Treatment with any anti-diabetic medications other than insulin within 4 weeks of&#xD;
             enrollment.&#xD;
&#xD;
        23. Use of any investigational agents within 4 weeks of enrollment. 24. Administration of&#xD;
        live attenuated vaccine(s) within 2 months of enrollment. 25. Any medical condition that,&#xD;
        in the opinion of the investigator, will interfere with the safe participation in the&#xD;
        trial.&#xD;
&#xD;
        26. Treatment with any immunosuppressive regimen at the time of enrollment. 27. A previous&#xD;
        islet transplant. 28. A previous pancreas transplant 29. Inflammatory bowel disease. 30.&#xD;
        History of intestinal obstructions. 31. Previous major abdominal surgery. 32. History of&#xD;
        peritonitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodolfo Alejandro</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes Research Institute, University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 7, 2014</study_first_submitted>
  <study_first_submitted_qc>August 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2014</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Rodolfo Alejandro</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>islet transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>undecided. This is a small phase 1/2 pilot trial.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

